Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $59,673.60 in Stock

Posted by Nicole Kennedy on Jan 24th, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 12,432 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $4.80, for a total value of $59,673.60. Following the sale, the insider directly owned 629,943 shares in the company, valued at $3,023,726.40. This represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total value of $29,280.12.
On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total value of $67,377.80.
On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total value of $61,200.95.
On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total value of $40,644.99.
On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total transaction of $64,071.30.
On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total transaction of $100,459.52.
On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total transaction of $127,653.45.
On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The shares were sold at an average price of $5.50, for a total transaction of $179,877.50.
On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $56,900.25.
On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The stock was sold at an average price of $6.09, for a total transaction of $19,457.55.

Clene Stock Down 2.0%

NASDAQ:CLNN opened at $5.31 on Friday. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The stock’s 50-day moving average price is $6.75 and its 200-day moving average price is $6.49. The stock has a market capitalization of $57.61 million, a PE ratio of -1.57 and a beta of 0.87.

Clene (NASDAQ:CLNN – Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Sell-side analysts expect that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CLNN. D. Boral Capital reissued a “buy” rating and issued a $23.00 price target on shares of Clene in a research note on Friday, January 9th. Benchmark reissued a “buy” rating on shares of Clene in a research note on Thursday, December 4th. UBS Group restated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Clene presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Read Our Latest Stock Analysis on Clene

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CLNN. Scoggin Management LP boosted its holdings in shares of Clene by 75.1% during the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after purchasing an additional 107,250 shares during the last quarter. Lunt Capital Management Inc. lifted its position in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after buying an additional 1,250 shares in the last quarter. Jane Street Group LLC purchased a new position in Clene during the second quarter worth approximately $47,000. Finally, Jones Financial Companies Lllp acquired a new position in Clene during the third quarter worth $29,000. 23.28% of the stock is owned by hedge funds and other institutional investors.

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).